Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Gains from Sales and Divestitures (2018 - 2025)

Sutro Biopharma's Gains from Sales and Divestitures history spans 8 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 45.26% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, up 45.26%, while the annual FY2024 figure was $1.7 million, 46.68% up from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $2.3 million at Sutro Biopharma, up from $2.0 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.3 million in Q3 2025 and bottomed at $147349.0 in Q1 2021.
  • The 5-year median for Gains from Sales and Divestitures is $896269.0 (2023), against an average of $972374.6.
  • The largest annual shift saw Gains from Sales and Divestitures soared 265.86% in 2021 before it soared 30.12% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $238724.0 in 2021, then soared by 159.99% to $620647.0 in 2022, then soared by 86.2% to $1.2 million in 2023, then soared by 46.68% to $1.7 million in 2024, then skyrocketed by 33.26% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Gains from Sales and Divestitures are $2.3 million (Q3 2025), $2.0 million (Q2 2025), and $1.6 million (Q1 2025).